Identifying stable polymorphs is vital for ensuring drug efficacy, stability, and manufacturability. Our XtalGazer™ CSP platform predicts all stable forms and mitigates transition risks to support robust drug development. Recently, our team successfully evaluated the relative stability of Forms A, B, and C of a targeted API across temperatures and determined the crystal structure of Form C—delivering results in just 8 weeks to de-risk the critical solid form selection process.
Our Approach:
- Predicted low-energy polymorphs including Forms A, B, and C using our high-accuracy CSP platform.
- Determined Form C’s crystal structure using CSP and validated the predicted structure with our proprietary XRPD indexing algorithm.
- Evaluated free energy trends and transition temperatures for low-risk solid form selection.
